Serum India gets nod to manufacture vaccine against Omicron
The Drug Controller General of India has given its nod to Serum Institute of India's proposal to manufacture vaccine against the fast-transmissible Omicron variant of Covid-19, for examination test and analysis, official sources said today.
The order of DCGI approval was issued on February 4, they said, reports our New Delhi correspondent.
The SII in collaboration with Novavax Inc is working on the development of a vaccine against Omicron which has powered the third wave of the pandemic across India.
It applied to the DCGI on January 6.
However, the third wave appears to be ebbing with the number of daily cases in India falling below 1 lakh in the last 24 hours.
Comments